StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to Hold

Seres Therapeutics (NASDAQ:MCRB) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

Other equities research analysts have also issued research reports about the stock. JPMorgan Chase & Co. lowered shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday, October 24th. Chardan Capital reissued a “buy” rating and issued a $1.25 price target on shares of Seres Therapeutics in a report on Wednesday, November 13th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $10.00 price objective on shares of Seres Therapeutics in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, Seres Therapeutics has an average rating of “Hold” and an average target price of $5.08.

Seres Therapeutics Price Performance

MCRB stock opened at $0.81 on Tuesday. The business has a fifty day moving average price of $0.83 and a 200 day moving average price of $0.91. Seres Therapeutics has a fifty-two week low of $0.54 and a fifty-two week high of $2.05. The stock has a market capitalization of $138.97 million, a price-to-earnings ratio of -3.54 and a beta of 2.06.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of MCRB. Virtu Financial LLC lifted its holdings in Seres Therapeutics by 44.8% during the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 18,191 shares in the last quarter. Providence Wealth Advisors LLC lifted its holdings in shares of Seres Therapeutics by 49.5% during the 2nd quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 25,250 shares in the last quarter. Point72 DIFC Ltd bought a new position in shares of Seres Therapeutics during the 2nd quarter valued at about $64,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Seres Therapeutics in the 2nd quarter valued at approximately $92,000. Finally, State Street Corp increased its stake in Seres Therapeutics by 12.9% during the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock worth $363,000 after purchasing an additional 43,700 shares in the last quarter. Institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.